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1. Introduction  
Mitochondrial encephalopathies (MEs) are characterized by an extreme clinical 
heterogeneity since they can involve different systems and manifest at distinct ages with 
variable course. Many affected individuals display a cluster of clinical features that fall into 
discrete syndromes - among syndromic pictures, epilepsy is relevant in myoclonic epilepsy 
with ragged-red fibers (MERRF), mitochondrial encephalomyopathy with lactic acidosis and 
stroke-like episodes (MELAS), neurogenic weakness with ataxia and retinitis pigmentosa 
(NARP), Alpers’ encephalopathy and Leigh syndrome (LS). However, many patients do not 
fit neatly into one particular syndrome, due to “overlapping” presentations (sharing 
symptoms of different syndromes) or atypical clusters of symptoms.  
Epilepsy is a frequent symptom also in non-syndromic patients, sometimes dominating the 
clinical presentation.  
2. Genetics 
Mitochondrial disorders derive from mutations of mitochondrial (mtDNA) or nuclear DNA 
(nDNA), which lead to the impairment of the mitochondrial respiratory chain activity or 
mitochondrial ATP synthesis. Mitochondrial disorders typically involve tissues or organs 
with high energy demand including peripheral nervous system (PNS), central nervous 
system (CNS), eyes, ears, heart, endocrine system, kidney, guts, and liver. Fever, infection 
and stress may aggravate the neurological symptoms. 
Generally, the genotype-phenotype correlation in mitochondrial disorders is poor, since the 
clinical phenotype is not only dependent on the type and pathogenicity of the DNA 
mutation, but it may also derive from other genetic and environmental factors.  
A possible mechanism of inheritance is maternal transmission of the mutations located in 
the mtDNA. It is noteworthy that variable amounts of the mutated mtDNA (mutation load) 
usually coexist with wild-type molecules in the different tissues, resulting in a 
“heteroplasmic state”. Moreover, the phenotypic expression of mtDNA mutations may be 
dependent on a threshold effect, which can be dissimilar in different tissues, in relation to 
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specific energy demand. Nuclear “modifier” genes, environmental factors, mtDNA 
haplotypes (polymorphisms) or clusters of mtDNA variants could also influence the 
expression of mtDNA.  
The mtDNA contains 37 genes: 13 encoding for subunits of the respiratory chain complexes 
I (ND1–6, ND4L), III (cytochrome b), IV (COX I-III) and V (ATPase6, ATPase8) (oxidative 
phosphorylation system, OXPHOS); 22 encoding for transfer RNAs (tRNAs); 2 for 
ribosomial RNAs (rRNAs). The mitochondrial genetic code differs from the universal 
genetic code since mtDNA is not protected by any repair mechanism, thus resulting prone 
to mutations; indeed mutation rates of mtDNA are 10 times higher than those of nDNA. 
MtDNA mutations are classified as either large-scale rearrangements (partial deletions or 
duplications) or point mutations. Rearrangements are frequently sporadic, while point 
mutations are commonly inherited.  
The nuclear genome encodes more than 95% of all proteins located in the mitochondria. An 
increasing number of clinical conditions have been associated with nDNA mutations, which 
may involve different genes. These genes have been divided into four groups, according to 
their function. First group includes genes encoding for structural components of the 
respiratory chain; second group genes encoding for assembly factors of the respiratory chain 
complexes; third group genes responsible for factors of mtDNA stability; fourth group genes 
involved in biogenesis of mitochondria (Finsterer, 2006). Mutations of the nDNA are 
inherited by autosomal mechanism. 
Nuclear-mitochondrial interactions play a fundamental role in cellular homeostasis. The 
optimal interaction between nuclear and mitochondrial encoded factors is essential for 
transcription and translation of mtDNA and also for the correct assembly and function of 
the OXPHOS system.  
In both maternal and autosomal inherited MEs, single or multiple defects of the respiratory 
chain can be detected in the blood cells or muscular specimens. However, biochemical 
analysis can also identify defective activity of the respiratory chain complexes (in particular 
complex I and IV) in case of mitochondrial DNA depletion (see for example the mtDNA 
depletion syndrome 4A, due to mutation in the nuclear gene encoding for mitochondrial 
polymerase gamma) or multiple deletions.  
3. Maternally inherited syndromes with epilepsy, associated with mtDNA 
mutations 
Among MEs characterized by maternal inheritance, generalized seizures and myoclonus are 
the main symptoms of MERRF (myoclonus epilepsy with ragged-red fibers) syndrome (MIM 
ID #545000). This syndrome, initially described by Fukuhara et al (1980), is characterized by 
myoclonus, seizures, progressive cerebellar syndrome, and ragged-red fibers in muscle biopsy. 
It can be due to mutations in more than one mitochondrial gene, e.g. MTTK, MTTL1, MTTH, 
MTTS1, MTTS2, MTTF and MTND5. However, a specific mtDNA mutation of the tRNA(Lys) 
gene (MTTK), implying an A-to-G transition at nucleotide 8344, accounts for 80 to 90% of 
MERRF cases (Shoffner and Wallace, 1992). Biochemically, this mutation produces multiple 
deficiencies in the enzyme complexes of the respiratory chain (typically complexes I and IV), 
consistent with a defect in translation of all mtDNA-encoded genes.   
A typical MERRF picture was observed in a patient bearing a mutation of the MTTF gene 
which codes tRNA(Phe) (Mancuso et al, 2004). 
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Myoclonus epilepsy may manifest at variable age and can associate with other symptoms 
including general weakness, muscle wasting, deafness, dementia, short stature, optic 
atrophy, peripheral neuropathy, cardiomyopathy, myoglobinuria  and renal tubular 
dysfunction (Wu et al, 2010). 
As an example of the heterogeneity affecting also well defined ME with epilepsy, we report 
here some features of a MERRF family, bearing the common MTTK mutation, including four 
affected siblings with similar symptoms, but clinically different severity. The proband, 
previously described by Roger et al. (1982), had typical and severe progressive myoclonus 
epilepsy associated with optic atrophy. His brother showed occasional seizures and 
photoparoxysmal EEG response. His sister had late-onset action myoclonus and 
photoparoxysmal EEG response (figure 1). 
 
 
A: EEG recording of a 58 years-old female patient with MERRF syndrome showing slow background 
activity and diffuse slow waves; EMG recording includes positive and negative myoclonic jerks.  
B: EEG recording of the 24 years-old son of the previous patient showing a sequence of diffuse slow 
waves; in this case, EMG shows regular muscular contraction.  
Fig. 1. Heterogeneous EEG-EMG features in the same family with MERRF syndrome 
His nephew showed decreased visual acuity, associated with photosensitive (but not action-
induced) myoclonus (figure 2).  
MELAS (MIM ID #540000) syndrome is characterized by mitochondrial myopathy, 
encephalopathy, lactic acidosis, and stroke-like episodes. The disorder is characterized by 
symptoms and signs of central nervous system involvement, including seizures, migraine, 
hemiparesis, hemianopsia, cortical blindness, and episodic vomiting. Other common 
symptoms are: hearing loss, reduced statural growth, diabetes (Ciafaloni et al, 1992). 
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MELAS syndrome can be caused by mutation in several genes of the mtDNA coding for 
tRNA or polypeptides, including MTTL1, MTTQ, MTTH, MTTK, MTTS1, MTND1, MTND5, 
MTND6, and MTTS2. The 3243A-G transition in the MTTL1 gene can be found in about 80% 
of the patients (Goto et al, 1992).  
 
 
A and B: EEG recording of a female patient with MERRF syndrome showing diffuse spike and slow 
waves prevalent on posterior derivations (boxes) with occasional spontaneous occurrence.  
C: Intermittent photic stimulation (IPS) induces an increase of the epileptic discharges.  
Fig. 2. Spontaneous and photically-induced epileptiform abnormalities in MERRF syndrome 
In MELAS syndrome, epilepsy is a frequent symptom; seizures are often of motor type and 
can be grouped in clusters (until the extreme picture of epilepsia partialis continua) even 
without the evidence of concomitant new acute brain insult (Canafoglia et al, 2004). 
However, a relationship between clusters of seizures and stroke-like episodes is common: 
focal neuronal hyperexcitability or epileptic activity may cause an increase of ATP demand 
which can be followed by depletion of ATP and consecutive vasogenic edema (Iizuka et al, 
2002 ; 2003). Finally, the vasogenic edema turns into laminar necrosis indicated by T1 
hyperintensity at cerebral MRI. Another explanation suggests that stroke like episodes are 
due to metabolic derangement, spreading beyond an ischemic focus. Figure 3 shows the 
dramatic change of EEG activity after repeated seizures, indicated by the appearance of 
subcontinuous focal slow waves, in a patient with MELAS syndrome. 
A syndrome characterized by features of both MERRF and MELAS (overlap MERRF-MELAS) 
has been described by Zeviani et al. (1993) in association with a point mutation at nucleotide 
8356 (T-to-C transition) in the MTTK gene. The phenotype was characterized by myoclonic 
epilepsy, neural deafness, ataxia, stroke-like episodes in the majority of the affected siblings 
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or rarely by the association of seizures with other symptoms. In other families with an 
overlap MERFF-MELAS, Nakamura et al. (1995) identified a heteroplasmic mutation in the 
MTTS1 gene, while Melone et al. (2004) reported a heteroplasmic mutation in the MTTH 
gene. 
 
 
A: EEG recording of a patient with MELAS syndrome showing asymmetric background activity and 
occasional diffuse spike and waves with posterior prevalence.  
B: After repeated seizures, the EEG recording of the same patient shows diffuse attenuation of the 
background activity and the appearance of subcontinuous slow waves on posterior derivations.  
Fig. 3. EEG changes in a patient with MELAS syndrome after repeated seizure occurrence 
Neurogenic muscle weakness, ataxia, and retinitis pigmentosa (NARP) syndrome typically 
presents with proximal motor neuropathy, sensory disturbances, cerebellar ataxia, and 
retinitis pigmentosa. More rare features include developmental delay, mental retardation, 
dementia, epilepsy, or cardiomyopathy.  
In some patients, NARP may clinically overlap with Leigh syndrome (NARP/MILS overlap) 
due to point mutations in the mitochondrial ATPase6 gene, presumably resulting in 
impaired ATP synthesis. In this syndrome usually associated with T8993G mutation, have 
been described infantile spasms with hypsarrithmia (Desguerre at al, 2003) 
4. Autosomal inherited syndromes with epilepsy, associated with nDNA 
mutations 
Other mitochondrial syndromes causing epilepsy are associated with multiple mtDNA 
deletions or tissue-specific depletions. These conditions are due to nuclear gene defects 
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involved in controlling the nuclear-mitochondrial intergenomic signaling (Spinazzola and 
Zeviani, 2005). 
These conditions include the following syndromes: 
Developmental delay or dementia, lactic acidosis, cyclic vomiting, seizures, failure to thrive, 
hearing loss, myopathy, liver failure, renal tubular acidosis, pancreatitis, manifesting at 1-3 
months, characterize childhood myo-cerebro-hepatopathy spectrum (MCHS). 
Myoclonic epilepsy, myopathy, sensory ataxia (MEMSA) is characterized by epilepsy, 
myopathy, ataxia without ophthalmoplegia (previously defined as spinocerebellar ataxia 
with epilepsy: SCAE). 
Ataxia neuropathy spectrum (ANS) is characterized by ataxia and neuropathy, seizures 
(reported in two-thirds of the patients), ophthalmoplegia (one-half), clinical myopathy 
(rare). This disorder was previously defined as recessive ataxia syndrome: MIRAS and 
sensory ataxia neuropathy dysarthria and ophthalmoplegia: SANDO. 
Autosomal Recessive progressive external ophthalmoplegia (arPEO) and Autosomal 
Dominant progressive external ophthalmoplegia (adPEO) are characterized by myopathy, 
variable sensorineural hearing loss, axonal neuropathy, ataxia, depression, parkinsonism, 
hypogonadism, and cataracts (previously defined as CPEO plus). Seizures are uncommon; 
however, few patients may have signs reminding those observed in MELAS syndrome, 
including stroke-like episodes and seizures (Deschauer et al, 2007). These syndromes are 
typically associated with mutations in the nuclear-encoded DNA polymerase-gamma gene 
(gene map locus: 15q25). 
The syndrome variably defined as Alpers' disease, Alpers' syndrome, Alpers-Huttenlocher’s 
disease, progressive neuronal degeneration of childhood, progressive sclerosing 
poliodystrophy or progressive infantile poliodystrophy is characterized by neuronal 
degeneration of the cerebral cortex and elsewhere, caused by recessive mutations in nDNA, 
coding for the mitochondrial DNA polymerase-gamma. In this syndrome, the onset is 
usually before age four years and up to age 25-35; often there is pre-existing developmental 
delays of variable severity. The syndrome is characterized by seizures, episodic 
psychomotor regression, liver dysfunction or failure, which may follow exposure to certain 
antiepileptic medication. The electro-clinical pattern is typically characterized by periodic 
EEG and epilepsia partialis continua.  
5. Leigh syndrome 
Leigh syndrome also defined as “subacute necrotizing encephalomyelopathy” is 
characterized by focal, bilateral, and symmetric necrotic lesions associated with 
demyelination, vascular proliferation, and gliosis in the brain stem, diencephalon, basal 
ganglia, cerebellum, and (occasionally) cerebral white matter. 
The syndrome has early onset with hypotonia, failure to thrive, psychomotor regression, 
and brain stem and basal ganglia dysfunction with ataxia, ocular movement abnormalities, 
dystonia, and swallowing and respiratory disturbances. It can be inherited as autosomal 
recessive trait or as autosomal dominant or X-linked mechanism, while other patients show 
maternal inheritance (MILS). It can be associated with functional or molecular defects in 
several enzyme systems (pyruvate dehydrogenase complex: PDHC), respiratory chain 
complexes I–IV (cytochrome c oxidase: COX), and mitochondria-encoded ATPase 6 subunit 
of complex V. 
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Molecular exams could identify heterogeneous mutations in various mitochondrial and 
nuclear genes coding for complex I, complex III and complex IV and complex V gene. 
Mutations have been found also in genes encoding mitochondrial tRNA proteins (MTTV, 
MTTK, MTTW, and MTTL1) and in components of the pyruvate dehydrogenase complex 
(e.g. PDHA1: X-linked Leigh syndrome). The French-Canadian (or Saguenay-Lac Saint Jean) 
type of Leigh syndrome with COX deficiency (LSFC) is caused by mutation in the LRPPRC 
gene. Deficiency of coenzyme Q10 can present as Leigh syndrome. 
In the Leigh syndrome, both generalized and focal seizures have been described, according 
to genetic and biochemical heterogeneity.  
6. Non-syndromic pictures 
Seizures can manifest in many patients with infantile MEs, who were diagnosed on the 
bases of their biochemical defects but still not classified genetically. Epilepsy may manifest 
as catastrophic neonatal forms, neonatal myoclonic encephalopathies, infantile spasms, 
refractory status epilepticus, epilepsia partialis continua, myoclonic epilepsy (El Sabbagh et 
al , 2010), Landau Kleffner, Lennox-Gastaut syndromes, unclassified generalized epilepsy or 
partial epilepsy (Canafoglia et al, 2001; Lee et al, 2008). Thus, epilepsy may be either focal or 
generalized and its severity varies in different case series, though the appearance of drug-
resistant seizures possibly marks a severe turn in the disease with high risk of neurological 
deterioration and fatal outcome (El Sabbagh et al , 2010). 
Among various biochemical defects, it’s worth noting complex I deficiency. Complex I 
deficiency, due to mutations in mtDNA genes coding for ND subunits, has been described 
in patients with heterogeneous syndromic (MELAS, Leigh) and non-syndromic MEs, 
frequently associated with severe epilepsy (Antozzi et al, 1995; Malfatti et al, 2007).  
Mitochondrial dysfunctions may be implicated also in sporadic forms of partial epilepsy 
such is temporal lobe epilepsy, since severe impairment of the respiratory chain activity has 
been detected in vitro on hippocampus samples from patients with drug resistant epilepsy. 
This observation was also supported by various evidences obtained in vivo using 
neuroimaging techniques (Zsurka and Kunz, 2010).  
7. Pyruvate dehydrogenase (PDH) Deficiency (MIM ID #312170) 
Pyruvate dehydrogenase complex (PDHC) is a mitochondrial matrix enzyme complex that 
catalyzes the oxidative decarboxylation of pyruvate to acetyl CoA, nicotinamide adenine 
dinucleotide (the reduced form, NADH), and CO2. This reaction constitutes the bridge 
between anaerobic and aerobic cerebral energy metabolism. The great majority of PDH 
complex deficiencies results from mutations in the X-linked pyruvate dehydrogenase (E1) 
alpha subunit gene (PDHA1). Gene map locus: Xp22.2-p22.1.  
The clinical severity can vary from early neonatal presentation with severe lactic acidosis to 
a progressive disease with mental retardation and neurological complications. Some females 
are only mildly affected or asymptomatic in relation to the pattern of X-inactivation.  
Epilepsy has been reported with a high frequency in children with PDH deficiency 
(Canafoglia et al, 2001; Kang et al, 2007). Epilepsy is frequently severe and may have 
variable characteristics including some forms of epileptic encephalopathy.   
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8. Guidelines for the recognition of patients with mitochondrial DNA disease 
Guidelines for recognition of patients with mitochondrial DNA disease should include the 
detection of the classic syndromes; however, in non-syndromic cases, may be useful the 
recognition of characteristic clinical features (for example, myoclonus) or specific 
combinations of symptoms (for example, strokes and migraine and seizures and ataxia). 
Typically, in the mitochondrial encephalopathies, the observed symptoms may be referred 
to the involvement of many organ systems, for example, diabetes and deafness.  
Besides the clinical observation, characteristic MRI findings may orientate the diagnostic 
work-up.  
Laboratory exams should include the determination of the lactic acidaemia, which is 
frequently elevated in children in case of mitochondrial encephalopathy. Finally, the 
muscle biopsy may reveal ragged-red fibres or cytochrome c oxidase-deficient fibres. 
(Falk, 2010) 
Among other symptoms, epileptic presentation may include isolated seizure or isolated 
status, intermittent seizures or status, severe epilepsies, focal or multifocal epilepsies, 
generalized seizures and myoclonus (mainly progressive myoclonus epilepsies).  
Though not always associated with MEs, myoclonus, epilepsia partialis continua, status 
epilepticus and intractable epilepsy should be considered common symptoms of these 
disorders.  
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